This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
anglais vers norvégien: In vitro Diagnistics General field: Médecine Detailed field: Médecine : médicaments
Texte source - anglais The NT-proBNP assay is a chemiluminescent microparticle immunoassay (CMIA) for the in vitro quantitative determination of N-terminal pro B-type natriuretic peptide in human serum and plasma.
SUMMARY
B-type natriuretic peptide (BNP) is a cardiac neurohormone synthesized and secreted in response to the stretching of cardiac myocytes and volume overload. It is derived from the precursor preproBNP which consists of a single domain and a 108 amino acid peptide. Once secreted, proBNP is cleaved to release the active hormone BNP (amino acids 77-108), together with the remaining N-terminal portion known as NT-proBNP (amino acids 1-76).
BIOLOGICAL PRINCIPLES OF THE PROCEDURE
The NT-proBNP assay is a two-step immunoassay for the quantitative determination of N-terminal pro B-type natriuretic peptide in human serum and plasma using CMIA technology with flexible assay protocols, referred to as Chemiflex.
1. Sample and biotinylated anti-NT-proBNP coated paramagnetic microparticles are combined. The NT-proBNP present in the sample binds to the biotinylated anti-NT-proBNP coated microparticles.
2. After washing, anti-NT-proBNP acridinium-labeled conjugate is added to create a reaction mixture.
3. Following another wash cycle, pre-trigger and trigger solutions are added to the reaction mixture.
4. The resulting chemiluminescent reaction is measured as relative light units (RLUs).
PREPARATION FOR ANALYSIS
• Follow the tube manufacturer’s processing instructions for specimen collection tubes.
• Mix thawed specimens thoroughly by low speed vortexing or by inverting 10 times. Visually inspect the specimens. If layering or stratification is observed, continue mixing until specimens are visibly homogeneous.
• To ensure consistency in results, recentrifuge specimens before testing if
• they contain fibrin, red blood cells, or other particulate matter
or
• they were frozen and thawed.
• Recentrifuge specimens at 10,000 RCF (relative centrifugal force) for 5 minutes before testing. If testing will be delayed more than 24 hours, remove serum or plasma from the clot, red blood cells, or separator gel prior to recentrifugation.
• Transfer clarified specimen to a sample cup or secondary tube for testing. For centrifuged specimens with a lipid layer, transfer only the clarified specimen and not the lipemic material.
• Inspect all specimens for bubbles. Remove bubbles with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.
Traduction - norvégien NT-proBNP-analysen er en immunkjemisk kjemiluminescensmikropartikkelanalyse (CMIA – chemiluminescent microparticle immunoassay) for in vitro kvantitativ bestemmelse av N-terminal pro B-type natriuretisk peptid i humant serum og plasma.
SAMMENDRAG
B-type natriuretisk peptid (BNP) er et hjertenevrohormon syntetisert og utskilt som respons på strekking av hjertemyocytter og volumoverbelastning. Det er avledet fra forstadiet preproBNP som består av ett enkelt domene og et 108-aminosyrepeptid. Når det er utskilt, spaltes proBNP for å frigjøre det aktive hormonet BNP (aminosyrene 77–108) sammen med den gjenværende N-terminale delen kjent som NT-proBNP (aminosyrene 1–76).
BIOLOGISKE PRINSIPPER FOR PROSEDYREN
NT-proBNP-analysen er en totrinns immunanalyse for kvantitativ bestemmelse av N-terminal pro B-type natriuretisk peptid i humant serum og plasma ved bruk av CMIA-teknologi med fleksible analyseprotokoller som kalles Chemiflex.
1. Prøven og biotinylerte anti-NT-proBNP-belagte paramagnetiske mikropartikler kombineres. NT-proBNP som finnes i prøven, binder seg til de biotinylerte anti-NT-proBNP-belagte mikropartiklene.
2. Etter vask tilsettes anti-NT-proBNP akridiniummerket konjugat for å lage en reaksjonsblanding.
3. Etter en ny vaskesyklus tilsettes pretrigger- og triggerløsninger til reaksjonsblandingen.
4. Kjemiluminescensreaksjonen dette fører til, måles som relative lysenheter (RLU-er – relative light units).
FORBEREDELSER TIL ANALYSEN
• Følg rørprodusentens behandlingsanvisning for prøvetakingsrørene.
• Bland tinte prøver godt med en vortex-mikser på lav hastighet eller ved å snu dem 10 ganger. Inspiser prøvene visuelt. Dersom du observerer lagdeling eller stratifikasjon, må du fortsette å blande til prøvene er synlig homogene.
• For å sikre konsistens i resultatene må du resentrifugere prøvene før testing dersom
• de inneholder fibrin, røde blodlegemer eller annen partikkelmaterie
eller
• de har blitt frosset og tint.
• Sentrifuger prøvene på nytt ved 10 000 RCF (relativ sentrifugalkraft) i 5 minutter før testing. Dersom testingen vil bli over 24 timer forsinket, fjerner du serum eller plasma fra det koagulerte blodet, de røde blodlegemene eller separatorgelen før ny sentrifugering.
• Overfør klarnet prøve til en prøveflaske eller et sekundærrør for testing. For sentrifugerte prøver med lipidlag overfører du bare den klarnede prøven, ikke det lipemiske materialet.
• Inspiser alle prøver for luftbobler. Fjern luftboblene med en applikatorpinne før analyse. Bruk en ny applikatorpinne for hver prøve for å forhindre krysskontaminering.
anglais vers norvégien: Stent General field: Médecine Detailed field: Médecine : cardiologie
Texte source - anglais Technical Part
DESCRIPTION
The XY is composed of two components: a device (stent system) and a drug product (a formulation of everolimus contained in a polymer coating). The Stent component is made from a platinum chromium alloy and is available in 4 models each designed for specific diameters. The coating is comprised of the inner layer, which is a primer for improving the adhesion of the outer layer and the outer layer which is a polymer matrix that contains an active pharmaceutical ingredient.
INDICATIONS FOR USE
The treatment of Critical Limb Ischemia or severe lower leg claudication in infrapopliteal lesions.
PRECAUTIONS
Care should be taken to control the position of the guide catheter/sheath tip during stent delivery, deployment, and balloon withdrawal.
Maintain guidewire placement across the lesion during the entire stent removal process. Carefully pull back the stent system until the proximal balloon marker of the stent system is just distal to the guide catheter/sheath distal tip.
Clinical Part
How will my research blood sample be used?
The sponsor of this study plans to conduct biomarker and pharmacokinetic research using your blood samples. Biomarkers are chemical "markers" in blood that may be related to how your body processes the study drug.
What are the side effects?
Because X is an investigational drug, the side effects are not completely known and serious side effects, including death, are a possibility. The side effects seen in previous studies conducted with X are: fatigue, shortness of breath, upper respiratory tract infection, low blood counts (red blood cells), abnormal liver function, and decreased kidney function.
Will my information be kept confidential?
Unless required by law, your name will not be disclosed outside the research clinic. It will be available only to the following people or agencies: the study doctor and staff; authorized representatives of the study doctor; ethics committees and the European Medicines Agency.
Traduction - norvégien Teknisk del
BESKRIVELSE
XY har to bestanddeler: en enhet (et stentsystem) og et legemiddelprodukt (en everolimusløsning i et polymerbelegg). Stentkomponenten er laget av en legering av platina og krom og er tilgjengelig i fire modeller. Hver av disse er utformet for spesifikke diametere. Belegget består av det indre laget, en primer som skal styrke adhesjonen av det ytre laget, og det ytre laget, en polymermatrise som inneholder en aktiv legemiddelingrediens.
INDIKASJONER FOR BRUK
Behandling av kritisk ekstremitetsiskemi eller alvorlig claudicatio i distale ekstremiteter (legger) ved infrapopliteale lesjoner.
FORHOLDSREGLER
Posisjonen av føringskateteret/hylsetuppen må kontrolleres nøye under innsetting og plassering av stenten samt under uttak av ballongen.
Bevar ledetråden over lesjonen under hele fjerningsprosessen av stenten. Trekk forsiktig tilbake stentsystemet til stentsystemets proksimale ballongmarkør akkurat er distalt fra føringskateteret/hylsens distale tupp.
Klinisk del
Hvordan skal forskningsblodprøven brukes?
Sponsoren for denne studien planlegger å gjennomføre forskning på biomarkører og [legemiddelets] farmakokinetikk ved hjelp av blodprøvene dine. Biomarkører er kjemiske markører i blodet som kan forbindes med hvordan kroppen reagerer på studiemedisinen.
Hva er bivirkningene?
Siden X er et legemiddel under utprøving, har vi ikke fullstendig oversikt over bivirkningene. Alvorlige bivirkninger, inkludert dødsfall, er ikke utelukket. Bivirkninger observert under tidligere studier gjennomført med X, er: tretthet, kortpustethet, øvre luftveisinfeksjon, lave blodverdier (røde blodlegemer), unormal leverfunksjon og nedsatt nyrefunksjon.
Vil opplysningene mine bli holdt konfidensielle?
Med mindre loven krever det, blir navnet ditt ikke gjort tilgjengelig utenfor forskningsklinikken. Det blir bare tilgjengelig for følgende personer eller byråer: studielegen og -personalet, autoriserte representanter for studielegen, etiske komiteer og Det europeiske legemiddelkontoret.
français vers norvégien: Tribune de Zineb - Le Monde / Kronikk av Zineb - Bergens Tidende General field: Sciences sociales Detailed field: Journalisme
Texte source - français http://www.lemonde.fr/societe/article/2015/01/09/zineb-el-rhazoui-de-charlie-hebdo-il-arrivait-que-l-on-dise-aux-collegues-je-vous-aime_4552554_3224.html
français vers norvégien: Tribune de Sarah Roubato - Mediapart / Kronikk av Sarah Roubato Bergens Tidende General field: Sciences sociales Detailed field: Journalisme
Texte source - français https://blogs.mediapart.fr/sarah-roubato/blog/201115/lettre-ma-generation-moi-je-nirai-pas-quen-terrasse
Rakel Saetre Benon respecte les pratiques professionnelles ProZ.com's - Liste des pratiques.
Professional objectives
Meet new translation company clients
Screen new clients (risk management)
Network with other language professionals
Get help with terminology and resources
Learn more about translation / improve my skills
Get help on technical issues / improve my technical skills
Learn more about the business side of freelancing
Buy or learn new work-related software
Improve my productivity
Learn more about interpreting / improve my skills
Learn more about additional services I can provide my clients
Stay up to date on what is happening in the language industry
Help or teach others with what I have learned over the years
Find a mentor
Meet new end/direct clients
Bio
With my Masters Degree in Literature & Translation, I've had a rich International Career as a Freelance Journalist & Translator for Norway's Top Newspapers, a Language Teacher for Business Executives & children and a Tour Guide / Interpreter in Norway, France, and Italy.
Since 2016, I have been living between Norway and France, working fulltime as a Freelance Translator for Agencies and Direct Clients.
As an experienced Translator, I am ISO compliant and Native in both Norwegian Language Forms - Yes, we do have two very similar Written Languages for only 5 million Norwegians ;) Every Norwegian speaker understand both Language Forms, but few can handle the grammar and spelling of both correctly. Most of my clients, need Translation into Bokmål, but some Leading International Enterprises and Government Bodies, have the obligation to use both. Some modern startups also appreciate the originality and local feeling that Nynorsk can offer.
I have three main specialities in Translation:
1. IT - I translate around 5000 words weekly for an International Leader in this field, and for various clients, I also often translate topics such as Robotics, Electronics, Marketing, e-shopping, e-learning, SaaS, UI, SEO, Business, and more.
2. Life Science - I have translated around 50 000 words in the Medical Field, for dfferent clients, through Translation Agencies.
3. Marketing / Transcreation - Benefiting from from my creative Writing Experience as a journalism, I have transcreated around 100 000 words og marketing Mterial in various Industries.
Membre depuis Dec '16
Compétences 